Cellectar Biosciences, Inc. — Director's Dealing 2021

Mar 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2021-03-12

Reporting Person: NEIS JOHN (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-12	Series A Warrants	$30.40	S	41155	Disposed	2021-04-20	Common Stock (4115)	Direct
2021-03-15	Series A Warrants	$30.40	S	11200	Disposed	2021-04-20	Common Stock (1120)	Direct
2021-03-16	Series A Warrants	$30.40	S	100515	Disposed	2021-04-20	Common Stock (10051)	Direct

Footnotes

F1: The price reported is a weighted average price. These warrants were sold in multiple transactions at prices ranging from $0.2648 and $0.27, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F2: The price reported is a weighted average price. These warrants were sold in multiple transactions at prices ranging from $0.265 and $0.2666, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3: The price reported is a weighted average price. These warrants were sold in multiple transactions at prices ranging from $0.28 and $0.34, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants sold at each separate price within the ranges set forth in footnote (3) to this Form 4.